Clinical Outcome and Prognostic Analysis of Young Adults Nasopharyngeal Carcinoma Patients of a Nonendemic Area in Intensity-Modulated Radiotherapy Era

Abstract

Aim: To investigate the clinical outcome and prognostic factors of young adults nasopharyngeal carcinoma (NPC) patients in the era of intensity-modulated radiotherapy. Methods: We retrospectively analyzed the clinical outcome and the prognostic factors of young adults NPC patients who were admitted to our hospital from January 2010 to December 2013. COX regression model was used to identify factors associated with survival. The acute and late toxicities were also evaluated. Results: A total of 165 patients were included; the median follow-up time for all the patients was 65 months (4–96 months). The 5-year overall survival (OS), distant metastasis-free survival, progression-free survival and local-regional recurrence-free survival were 85.9, 82.4, 76.4 and 92.4%, respectively. N stage was an independent prognostic factor for OS (p = 0.009) and distant metastasis-free survival (p = 0.008). Cumulative cisplatin >200 mg/m² was an independent prognostic factor for OS (p = 0.032). Conclusion: Young adults with NPC can achieve a reasonable local-regional control and OS in the era of intensity-modulated radiotherapy with tolerable toxicities.

Keywords::

• IMRT
• intensity-modulated radiotherapy
• nasopharyngeal carcinoma
• young adults patients

Financial & competing interests disclosure

The study was supported by research grants from Chinese Society of Clinical Oncology (CSCO) Clinical Oncology Research Funding (Y-MT2016-017), and Science and Technology Program Project Funds of Sichuan Province (grant/award number: “2015SZ0053”). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Additional information

Funding

The study was supported by research grants from Chinese Society of Clinical Oncology (CSCO) Clinical Oncology Research Funding (Y-MT2016-017), and Science and Technology ProgramProject Funds of Sichuan Province (grant/award number: “2015SZ0053”). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.